|
Volumn 42, Issue 6, 2007, Pages 510-511
|
Is oral combination therapy with a proton-pump inhibitor and H2 receptor antagonist effective as initial treatment? [4]
a a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CYTOCHROME P450 2C19;
HISTAMINE H2 RECEPTOR ANTAGONIST;
LAFUTIDINE;
LANSOPRAZOLE;
PROTON PUMP INHIBITOR;
ADULT;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DATA ANALYSIS;
GENOTYPE;
HUMAN;
HUMAN EXPERIMENT;
LETTER;
MALE;
MONOTHERAPY;
NORMAL HUMAN;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
STATISTICAL ANALYSIS;
STOMACH PH;
2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES;
ACETAMIDES;
ADMINISTRATION, ORAL;
ADULT;
DRUG THERAPY, COMBINATION;
HISTAMINE H2 ANTAGONISTS;
HUMANS;
MALE;
PIPERIDINES;
PROTON PUMPS;
PYRIDINES;
|
EID: 34447330127
PISSN: 09441174
EISSN: 14355922
Source Type: Journal
DOI: 10.1007/s00535-007-2024-1 Document Type: Letter |
Times cited : (3)
|
References (4)
|